Clinical trial
Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00280098 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00280098 |
|---|---|
| Title | Docetaxel in the Treatment of Hormone Refractory Prostate Cancer |
| Official title | Phase IV Study of Safety and Efficacy of Docetaxel in Combination With Prednisone in Advanced Hormone Refractory Prostate Cancer Treatment |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | docetaxel |
| Enrollment | 30 |
| Start date | Jan 1, 2006 |
| Primary completion | Oct 1, 2007 |
| First posted | Jan 20, 2006 |
| Last update posted | Dec 7, 2009 |
| Countries | Czechia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: